Zenas BioPharma, Inc.
ZBIO
$32.36
-$0.69-2.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | -- | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | -- | 0.00 | -- | -- |
| Cost of Revenue | 62.91M | 60.44M | 55.72M | 34.40M | 43.03M |
| Gross Profit | -61.91M | -60.44M | -55.72M | -34.40M | -43.03M |
| SG&A Expenses | 15.75M | 16.91M | 15.59M | 13.18M | 12.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.66M | 77.35M | 71.31M | 47.58M | 55.16M |
| Operating Income | -77.66M | -77.35M | -71.31M | -47.58M | -55.16M |
| Income Before Tax | -111.34M | -80.99M | -240.34M | -51.50M | -52.20M |
| Income Tax Expenses | 114.00K | -- | 106.00K | -- | 20.00K |
| Earnings from Continuing Operations | -111.46M | -80.99M | -240.44M | -51.50M | -52.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.46M | -80.99M | -240.44M | -51.50M | -52.22M |
| EBIT | -77.66M | -77.35M | -71.31M | -47.58M | -55.16M |
| EBITDA | -77.66M | -77.34M | -71.30M | -47.57M | -55.15M |
| EPS Basic | -1.77 | -1.46 | -4.54 | -1.22 | -1.25 |
| Normalized Basic EPS | -0.81 | -0.91 | -0.87 | -0.69 | -0.78 |
| EPS Diluted | -1.77 | -1.46 | -4.54 | -1.22 | -1.25 |
| Normalized Diluted EPS | -0.81 | -0.91 | -0.87 | -0.69 | -0.78 |
| Average Basic Shares Outstanding | 63.11M | 55.62M | 53.00M | 42.16M | 41.87M |
| Average Diluted Shares Outstanding | 63.11M | 55.62M | 53.00M | 42.16M | 41.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |